Form 4: Ionis Pharmaceuticals EVP Sells Shares After Performance-Based Stock Units Vest

Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals, sold 1,523 shares of common stock after the vesting of performance-based restricted stock units.

Summary

• Elizabeth L. Hougen, the EVP, Finance & CFO of Ionis Pharmaceuticals, engaged in transactions involving the company's common stock.
• On January 30, 2025, she acquired 4,138 shares upon the vesting of performance-based restricted stock units (PRSUs).
• These PRSUs vested based on the company's relative total shareholder return compared to a peer group, resulting in a 150% payout of target shares.
• On January 31, 2025, she sold 1,523 shares at a weighted average price of $32.4384.
• Following these transactions, Hougen directly owns 110,500 shares of Ionis Pharmaceuticals.
• The sales occurred at prices ranging from $32.00 to $32.81.

Sentiment

Score: 6

Explanation: Neutral sentiment. The vesting of PRSUs is a positive sign of performance, but the subsequent sale of shares introduces a slightly negative element, though it's likely part of a pre-planned strategy.

Positives

• The vesting of PRSUs at 150% suggests strong performance relative to peers based on total shareholder return.

Negatives

• The sale of shares by a high-ranking executive could be interpreted negatively by some investors, although it may be part of a pre-planned strategy.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is not necessarily the case here.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The vesting of performance-based equity awards is tied to company performance, and subsequent sales are often part of executives' personal financial planning.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PRSUs to align management's interests with those of shareholders.
• Vesting criteria based on relative total shareholder return are a common benchmark in the pharmaceutical industry, as they directly measure a company's performance against its peers.
• Comparing Ionis Pharmaceuticals' TSR performance to companies like Alnylam Pharmaceuticals, Biogen, and Vertex Pharmaceuticals would provide further context on the vesting level achieved.

Stakeholder Impact

• The vesting of PRSUs and subsequent stock sale may have a minor impact on shareholder sentiment.

Key Dates